**Schweitzer Engineering Laboratories Expands into Medical Device for Autism Detection**

Schweitzer Engineering Laboratories (SEL), based in Pullman, is branching out from its traditional focus on power systems to develop a medical device aimed at early autism detection.

Dr. Georgina Lynch has been appointed as the principal scientist to lead this initiative. She previously developed the device prototype at Washington State University and brings over 20 years of experience in working with children with autism, along with a PhD in neuroscience/psychology.

The device is designed to simplify the screening process for autism, allowing for detection of signs of autism spectrum disorder in children as young as 24 months by measuring pupil light reflex. This innovation aims to be used during routine examinations, potentially facilitating earlier intervention and enhancing outcomes for affected children.

Dr. Lynch emphasized the significance of early intervention, stating, “It can mean the difference between a child acquiring verbal speech or remaining nonverbal. With the average diagnosis age at 49 months, this technology could lower that age due to its objectivity, giving children up to two extra years of crucial intervention.”

Currently, Lynch and her team are navigating the FDA approval processes as they work towards bringing this medical device to market. This marks SEL’s first entry into the field of medical device manufacturing.

The announcement of this project follows a recent leadership change at SEL, with CEO Dave Whitehead stepping in after Ed Schweitzer announced his decision to step down as President.

For further details, visit the Wavelength: Early ASD Detection Technology page at the Elson S. Floyd College of Medicine, Washington State University.